Public biotech in 2016—the numbers
Chris Morrison, Riku Lähteenmäki
Index: 10.1038/nbt.3917
Full Text: HTML
Abstract
The anticipated decline in the biotech industry's ability to raise capital from public investors and an accompanying slump in biotech markets materialized in 2016, but all is not gloom and doom.
Latest Articles:
A wellness study of 108 individuals using personal, dense, dynamic data clouds
2017-07-17
[10.1038/nbt.3870]
Nanoscale imaging of clinical specimens using pathology-optimized expansion microscopy
2017-07-17
[10.1038/nbt.3892]
Wanted: biotech for an aging population
2017-07-12
[10.1038/nbt.3925]
An emerging model for life sciences commercialization
2017-07-12
[10.1038/nbt.3911]
CRISPR–Cas9 claim sets and the potential to stifle innovation
2017-07-12
[10.1038/nbt.3913]